Article

Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMD

2026-06-16

Abstract excerpt

<title>Abstract</title> <p> Neovascularization in wet age-related macular degeneration (AMD) is caused by upregulation of vascular endothelial growth factor (VEGF-A) expression. It leads to vascular leakage, abnormal vessel growth, hemorrhage, and retinal cell death, leading to irreversible vision loss. Current anti-VEGF therapies, including Eylea® and Vabysmo®, provide clinical benefit but require frequent intr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3ac12174-b7fd-5789-9b83-2720d6d87140
DOI: 10.21203/rs.3.rs-10021402/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMDDOI 10.21203/rs.3.rs-10021402/v1Read

Targeting vascular endothelial growth factor using retinal gene therapySemantic proximity Read

Gene therapy for age-related macular degeneration: a promising frontier in vision preservationSemantic proximity Read

A New Generation of Gene Therapies as the Future of Wet AMD TreatmentSemantic proximity Read

New Generation of Gene Therapies as the Future of Wet AMD TreatmentSemantic proximity Read

Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular DegenerationSemantic proximity Read

Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnologySemantic proximity Read

Engineered virus-like particle-assembled VEGF-targeting Cas9 ribonucleoprotein treatment alleviates neovascularization in wet age-related macular degenerationSemantic proximity Read

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degenerationSemantic proximity Read

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applicationsSemantic proximity Read

GB10, a best-in-class antibody fusion protein targeting VEGF/Ang-2, exhibits promising therapeutic efficacy for neovascular eye diseasesSemantic proximity Read

Evaluation of Collagen-Derived peptide (EB-203) for Treating Wet Age-Related Macular DegenerationSemantic proximity Read

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity Read